4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-020206
CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.29 ($278,646)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-07-21 | Sale : show line 1 in the form 10b5-1 | −11,924 | $22.26 | $265,458 | 953,264 | I |
| 2025-07-21 | Sale : show line 2 in the form 10b5-1 | −576 | $22.90 | $13,188 | 952,688 | I |
| Open-market sales · 12,500 sh · avg $22.29 · $278,646 | ||||||
Loading xslF345X05/form4-07232025_100717.xml…